C
Cezary Szczylik
Researcher at Medical University of Warsaw
Publications - 291
Citations - 30393
Cezary Szczylik is an academic researcher from Medical University of Warsaw. The author has contributed to research in topics: Renal cell carcinoma & Cancer. The author has an hindex of 49, co-authored 274 publications receiving 27380 citations. Previous affiliations of Cezary Szczylik include Military Medical Academy & Cora.
Papers
More filters
Journal ArticleDOI
Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer
TL;DR: Three patients treated with sunitinib and sorafenib who developed chronic myeloid leukaemia during treatment for ccRCC are reported, proposing a molecular mechanism of tyrosine kinase inhibitors action on bone marrow cells that might be co-responsible for CML development.
Journal ArticleDOI
Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
TL;DR: This study suggests that transplantation of hematopoietic stem cell using alemtuzumab, fludarabine and melphalan as a conditioning therapy is safe, inexpensive and effective treatment for patients with severe aplastic anemia, including multi-transfused adults having their disease for a long time.
Journal ArticleDOI
Thyroid Hormones as Renal Cell Cancer Regulators.
TL;DR: Thyroid hormone and its receptor are presented as a regulator of renal cell carcinoma.
Journal ArticleDOI
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer
TL;DR: It was shown that the proliferation rate of cancer stem cells was decreased by the tyrosine kinase inhibitors and the efficacy of the growth inhibition was limited by hypoxic conditions and 3D intratumoral cell-cell interactions.
Journal ArticleDOI
Future perspectives for mTOR inhibitors in renal cell cancer treatment.
TL;DR: This work discusses renal cell carcinoma cancer stem cells as a potential target for mTOR inhibitors and presents new concepts on emerging antiangiogenic therapies and points why systems biology approach with reverse molecular engineering may also contribute to the field of drug discovery in renalcell carcinoma.